Corcept Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Corcept Therapeutics (CORT).

Price Target Range — 12 Quarters

Analyst Consensus — 6 Analysts

5Buy

1Sell

Consensus RatingBuy# Analysts6Avg. Consensus PT$127Upside to Avg. PT+9.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 18, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$165
Jul 30, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$88→$165
Jul 30, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$150→$161
Jul 30, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$95→$165
Jul 29, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$135→$150
Jul 27, 2026	Wolfe Research	Kalpit Patel	Downgrade	Peer Perform→Underperform	$50
May 28, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$110→$135
May 28, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$75→$95
May 13, 2026	UBS	Ashwani Verma	Upgrade	Neutral→Buy	$44→$72
May 4, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$60→$75
May 1, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$73→$88
Mar 26, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$100→$110
Mar 26, 2026	Wolfe Research	Kalpit Patel	Upgrade	Underperform→Peer Perform	—
Mar 25, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$67→$60
Feb 25, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$67→$60
Feb 20, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$105→$67
Jan 23, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$99→$100
Jan 23, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$90→$105
Jan 2, 2026	Canaccord Genuity	Edward Nash	PT Cut	Buy	$140→$99
Jan 2, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$145→$90

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $165 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintains $165 price target.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $165

Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics (NASDAQ:CORT) with a Overweight and raises the price target from $88 to $165.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $161

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $150 to $161.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $165

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $95 to $165.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $150

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $135 to $150.

Benzinga Newsdesk

This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday

Top Wall Street analysts changed outlook on several top stocks. See all changes on analyst ratings page.

Avi Kapoor

Corcept Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Corcept Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $165 Price Target

PRO
Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $165

PRO
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $161

PRO
HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $165

PRO
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $150

This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday

People Also Watch

People Also Watch

Corcept Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Corcept Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $165 Price Target

PROPiper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $165

PROCanaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $161

PROHC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $165

PROCanaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $150

This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $165 Price Target

PRO
Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $165

PRO
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $161

PRO
HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $165

PRO
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $150